Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.

Emmanuelle JacquetFiona PhamBilly TaoukGhania Kerouani-LafayeAdrien MonardLiora BrunelNicolas Albin

Published in: Cancer chemotherapy and pharmacology (2023)

Over the past 15 years, clinical trials and the French early access program have allowed considerable early access to therapeutic innovation in real life for patients, especially in thoracic oncology.

Keyphrases

clinical trial
quality improvement
end stage renal disease
ejection fraction
chronic kidney disease
palliative care
spinal cord
prognostic factors
peritoneal dialysis
phase ii
spinal cord injury
patient reported outcomes
patient reported